Acarix AB (publ) operates as a medical technology enterprise, specializing in the development of swift, AI-powered diagnostic tools designed to exclude coronary artery disease (CAD). These solutions are deployed both within Sweden and on an international scale. The company's principal product is the CADScor System, an innovative diagnostic support device intended for immediate patient assessment. This system leverages precise acoustic measurements and sophisticated artificial intelligence algorithms to scrutinize blood flow within a patient's coronary arteries. Established in 2009, the firm maintains its corporate headquarters in Malmö, Sweden.
—
Acarix AB (publ) operates as a medical technology enterprise, specializing in the development of swift, AI-powered diagnostic tools designed to exclude coronary artery disease (CAD). These solutions are deployed both within Sweden and on an international scale. The company's principal product is the CADScor System, an innovative diagnostic support device intended for immediate patient assessment. This system leverages precise acoustic measurements and sophisticated artificial intelligence algorithms to scrutinize blood flow within a patient's coronary arteries. Established in 2009, the firm maintains its corporate headquarters in Malmö, Sweden.
—
Daily adjusted close
Acarix AB (publ) operates as a medical technology enterprise, specializing in the development of swift, AI-powered diagnostic tools designed to exclude coronary artery disease (CAD). These solutions are deployed both within Sweden and on an international scale. The company's principal product is the CADScor System, an innovative diagnostic support device intended for immediate patient assessment. This system leverages precise acoustic measurements and sophisticated artificial intelligence algorithms to scrutinize blood flow within a patient's coronary arteries. Established in 2009, the firm maintains its corporate headquarters in Malmö, Sweden.